Comprehensive Therapy in Osteoporosis Using a Single Drug: From ADFR to Strontium Ranelate

Title: Comprehensive Therapy in Osteoporosis Using a Single Drug: From ADFR to Strontium Ranelate

Volume: 13 Issue: 13

Author(s): C. Manette, J. Collette, N. Sarlet, A. Tancredi, B. Zegels and J.- Y. Reginster

Affiliation:

Keywords: Osteoporosis, treatment, fractures, strontium ranelate

Abstract: In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranelate induced a dosedependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase II dose ranging trial Strontium ranelate (500 mg, 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study, the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranelate was + 7.3%, a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study, evaluating the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranelate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age ≤74 years and Femoral Neck T score ≤-2.4 according to NHANES normative value). All these results suggest that strontium ranelate is a new, effective and safe treatment of vertebral and non-vertebral osteoporosis, with a unique mode of action.

Cite this article as:

Manette C., Collette J., Sarlet N., Tancredi A., Zegels B. and Reginster Y. J.-, Comprehensive Therapy in Osteoporosis Using a Single Drug: From ADFR to Strontium Ranelate, Current Medicinal Chemistry 2006; 13 (13) . https://dx.doi.org/10.2174/092986706777442057